Exelixis, Inc. (Nasdaq: EXEL) announced that its collaborator Genentech, a member of the Roche Group (OTC: RHHBY), will present preliminary ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Piper Jaffray Upgrades Exelixis (EXEL) to OverweightOctober 10, 2016 9:09 AM Genentech (RHHBY) Announces Significant Data from TECENTRIQ Phase 3 Data in Specific Lung CancerOctober 10, 2016 6:29 AM Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary TumorsOctober 7, 2016 7:36 AM Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 CongressOctober 7, 2016 4:01 AM Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary TumorsOctober 7, 2016 4:00 AM Form CT ORDER EXELIXIS, INC. October 6, 2016 10:47 AM